GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated January 13, 2026, serves as a transaction notification for the month of January 2026. The document details share transactions executed by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with the company. The filing confirms GSK's status as a foreign private issuer filing under Form 20-F.
Key Financial Metrics and Transaction Details
The filing does not contain consolidated financial statements, revenue, profit, or cash flow data. Instead, it reports specific share acquisition activities related to dividend reinvestment and share reward plans.
- Dividend Reinvestment (Share Reward Plan): Executed on January 8, 2026, on the London Stock Exchange (XLON). Ordinary shares were acquired at prices ranging from £18.9433 to £18.9464. American Depositary Shares (ADSs) were acquired on the New York Stock Exchange (XNYS) at prices ranging from $50.2200 to $50.4345.
- Deferred Annual Bonus Plan: Executed on January 9, 2026. Notional interest in Ordinary Shares increased at a price of £18.9100. Notional interest in ADSs increased at a price of $50.2200.
- Share Reward Plan (Partnership/Matching): Executed on January 12, 2026. Ordinary shares were acquired at a price of £18.9321.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. The reported changes are limited to the increase in shareholdings of specific executives and directors resulting from standard compensation and dividend reinvestment mechanisms.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Investor Verification Checklist
- Dividend Payment Date: Verify the dividend payment date of January 8, 2026, to confirm the timing of the reinvestment transactions.
- Share Price Consistency: Confirm that the transaction prices (approx. £18.91–£18.95 and $50.22–$50.43) align with the market closing prices on the respective transaction dates.
- Executive Participation: Note that transactions involved key leadership, including CEO Luke Miels, CFO Julie Brown, and various Presidents and Non-Executive Directors.
- Plan Mechanics: Distinguish between actual share acquisitions (Share Reward Plan) and increases in notional interest (Deferred Annual Bonus Plan).